Deng Isaac, Bobrovskaya Larisa
Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Neural Regen Res. 2022 Nov;17(11):2413-2417. doi: 10.4103/1673-5374.331866.
Parkinson's disease, the most common movement disorder, has a strong neuroinflammatory aspect. This is evident by increased pro-inflammatory cytokines in the serum, and the presence of activated microglial cells, and inflammatory cytokines in the substantia nigra of post-mortem brains as well as cerebrospinal fluid of Parkinson's disease patients. The central and peripheral neuroinflammatory aspects of Parkinson's disease can be investigated in vivo via administration of the inflammagen lipopolysaccharide, a component of the cell wall of gram-negative bacteria. In this mini-review, we will critically evaluate different routes of lipopolysaccharide administration (including intranasal systemic and stereotasic), their relevance to clinical Parkinson's disease as well as the recent findings in lipopolysaccharide mouse models. We will also share our own experiences with systemic and intrastriatal lipopolysaccharide models in C57BL/6 mice and will discuss the usefulness of lipopolysaccharide mouse models for future research in the field.
帕金森病是最常见的运动障碍疾病，具有很强的神经炎症特征。血清中促炎细胞因子增加、死后大脑黑质以及帕金森病患者脑脊液中存在活化的小胶质细胞和炎性细胞因子，都证明了这一点。帕金森病的中枢和外周神经炎症特征可通过给予炎性介质脂多糖（革兰氏阴性菌细胞壁的一种成分）在体内进行研究。在这篇小型综述中，我们将批判性地评估脂多糖的不同给药途径（包括鼻内、全身和立体定向给药）、它们与临床帕金森病的相关性以及脂多糖小鼠模型的最新研究结果。我们还将分享我们在C57BL/6小鼠中建立全身和纹状体内脂多糖模型的经验，并讨论脂多糖小鼠模型在该领域未来研究中的实用性。
